PURE Bioscience (PURE) Stock Price, News & Analysis

Company Overview

PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a food contact surface sanitizer and disinfectant; PURE Control, a food contact processing aid for fresh produce and raw poultry; PURE Multi-Purpose and Floor Cleaner Concentrate to clean various resilient surfaces, including floors, glass, and food contact surfaces; and PURE Multi-Purpose Hi-Foam Cleaner Concentrate to clean stainless steel equipment, resilient floors, walls, and painted surfaces. The company also provides Axen30, a hard surface disinfectant; Axenohl, an antimicrobial formulation for use as a raw material ingredient in the manufacturing of consumer and commercial disinfecting and sanitizing products; and SILVÉRION, an antimicrobial formulation that is used against bacteria, viruses, yeasts, and molds. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California.

Key Stats

• Today's Range: $0.09 to $0.12
• 50-Day Range: $0.06 to $0.11
• 52-Week Range: $0.05 to $0.21
• Volume: 107,610 shs
• Average Volume: 52,927 shs
• Market Capitalization: $10.58 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PURE Bioscience Stock Analysis - MarketRank™

PURE Bioscience scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for PURE Bioscience.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of PURE Bioscience is -2.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of PURE Bioscience is -2.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.01% of the float of PURE Bioscience has been sold short.

Short Interest Ratio / Days to Cover

PURE Bioscience has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in PURE Bioscience has recently increased by 42.00%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

PURE Bioscience does not currently pay a dividend.

Dividend Growth

PURE Bioscience does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.01% of the float of PURE Bioscience has been sold short.

Short Interest Ratio / Days to Cover

PURE Bioscience has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in PURE Bioscience has recently increased by 42.00%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

News Sentiment

PURE Bioscience has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, PURE Bioscience insiders have not sold or bought any company stock.

Percentage Held by Insiders

43.54% of the stock of PURE Bioscience is held by insiders. A high percentage of insider ownership can be a sign of company health.

PURE Stock Analysis - Frequently Asked Questions

How have PURE shares performed this year?

PURE Bioscience's stock was trading at $0.0638 on January 1st, 2025. Since then, PURE shares have increased by 48.3% and is now trading at $0.0946.

How were PURE Bioscience's earnings last quarter?

PURE Bioscience (OTCMKTS:PURE) issued its earnings results on Monday, June, 16th. The company reported ($0.01) EPS for the quarter. The business earned $0.49 million during the quarter.

How do I buy shares of PURE Bioscience?

Shares of PURE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of PURE Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some other companies that PURE Bioscience investors own include Meta Platforms (META), Hydrofarm Holdings Group (HYFM), Twilio (TWLO), NVIDIA (NVDA), Overstock.com (OSTK), Enphase Energy (ENPH) and Novavax (NVAX).

Company Calendar

• Last Earnings: 6/16/2025
• Today: 8/23/2025
• Fiscal Year End: 7/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Chemicals
• Current Symbol: OTCMKTS:PURE
• CIK: 1006028
• Web: www.purebio.com
• Phone: (619) 596-8600
• Fax: 619-596-8790
• Employees: 10
• Year Founded: 1992

Profitability

• EPS (Trailing Twelve Months): ($0.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.35 million
• Net Margins: -147.72%
• Pretax Margin: -147.72%
• Return on Equity: N/A
• Return on Assets: -334.78%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.08
• Quick Ratio: 0.94

Sales & Book Value

• Annual Sales: $1.96 million
• Price / Sales: 5.40
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.03) per share
• Price / Book: -3.15

Miscellaneous

• Outstanding Shares: 111,890,000
• Free Float: 63,171,000
• Market Cap: $10.58 million
• Optionable: Not Optionable
• Beta: 0.38